What are the indications for dual antiplatelet therapy (aspirin and clopidogrel) in patients with recent non‑cardioembolic ischemic stroke or high‑risk transient ischemic attack?

Dual Antiplatelet Therapy (DAPT) in Stroke

For patients with minor non-cardioembolic ischemic stroke (NIHSS ≤3-5) or high-risk TIA (ABCD2 ≥4), initiate DAPT with aspirin plus clopidogrel within 12-24 hours of symptom onset and continue for 21 days, followed by single antiplatelet therapy. 1, 2

Primary Indication: Minor Stroke or High-Risk TIA

The most robust evidence supports DAPT specifically for:

• Minor ischemic stroke with NIHSS ≤3 (some guidelines extend to NIHSS ≤5)
• High-risk TIA defined as ABCD2 score ≥4
• Non-cardioembolic mechanism (excludes atrial fibrillation requiring anticoagulation)

Timing and Duration

Critical timing window:

• Start DAPT ideally within 12-24 hours of symptom onset (maximum 7 days) 1, 2
• Continue for 21 days (some protocols extend to 30-90 days) 1, 2
• Then transition to single antiplatelet therapy for long-term prevention

Loading doses are essential:

• Aspirin: 160-325 mg loading dose 1
• Clopidogrel: 300-600 mg loading dose 1

Regimen Options

First-line DAPT regimen:

• Aspirin 81 mg daily + Clopidogrel 75 mg daily 1, 2

Alternative regimen:

• Aspirin 75-100 mg daily + Ticagrelor 90 mg twice daily for 30 days (loading: aspirin 300-325 mg + ticagrelor 180 mg) 1, 2
• Note: Ticagrelor carries higher bleeding risk, particularly intracranial hemorrhage 2

Evidence Base

The recommendation is based on pooled analysis showing DAPT reduces stroke recurrence by approximately 24-32% when initiated early and used short-term 3, 4, 5. The benefit is concentrated in the first 21 days, with most events prevented within the first 10 days 4, 5.

Key efficacy data:

• Stroke recurrence reduction: RR 0.68-0.76 compared to aspirin alone 3, 6, 5
• Absolute risk reduction: approximately 2-3% 3, 5
• Number needed to treat: approximately 50 patients to prevent one stroke 5

Safety Considerations

Bleeding risk increases with DAPT:

• Major bleeding: RR 2.17-2.42 with DAPT vs single therapy 3, 6
• Absolute increase: 0.2-0.3% 3, 5
• Risk is higher with ticagrelor than clopidogrel 6, 7
• Risk increases substantially if continued beyond 21-30 days 3, 4

Critical exclusion criteria:

• High bleeding risk patients
• Intracranial hemorrhage on neuroimaging (must be ruled out before starting DAPT)
• Cardioembolic stroke requiring anticoagulation 1

What NOT to Do

Long-term DAPT is contraindicated:

• Do NOT continue aspirin plus clopidogrel beyond 90 days 8, 9, 10, 9, 2
• The MATCH trial demonstrated no benefit and increased bleeding with long-term DAPT 9
• Hemorrhage risk outweighs any potential benefit after the acute period 3

Not indicated for:

• Moderate-to-severe stroke (NIHSS >5) - insufficient evidence and higher bleeding risk
• Cardioembolic stroke - anticoagulation is preferred 11
• Patients already on antiplatelet therapy at time of stroke - no evidence for escalation 10, 2

Long-Term Secondary Prevention

After completing 21-90 days of DAPT, transition to single antiplatelet therapy 10, 2:

Acceptable options (all Class I recommendations):

• Aspirin 81-325 mg daily, OR
• Clopidogrel 75 mg daily, OR
• Aspirin 25 mg + extended-release dipyridamole 200 mg twice daily 10, 2

Choice depends on tolerability, cost, and comorbidities. Clopidogrel or aspirin-dipyridamole may have slight superiority over aspirin alone 10, 2.

Common Pitfalls

1. Starting DAPT too late: Benefit diminishes significantly if not started within 24 hours 4, 5
2. Continuing DAPT too long: Bleeding risk escalates after 21-30 days without additional benefit 3, 4
3. Using DAPT in moderate-severe stroke: No evidence of benefit and higher bleeding risk
4. Forgetting loading doses: Initial loading doses are critical for rapid platelet inhibition 1
5. Missing cardioembolic etiology: These patients need anticoagulation, not DAPT 11